A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.

Trial Details

NCT ID
NCT05911217
Phase
PHASE1
Sponsor
CARsgen Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • CT041 autologous CAR T-cell injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667
  • Changsha, Hunan, China|28.19874,112.97087
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able t…
  • Aged 18 to 79 years;
  • Histologically confirmed pancreatic ductal adenocarcinoma;
  • Macroscopic complete tumor removal (R0 or R1 resection);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →